68 related articles for article (PubMed ID: 20661132)
1. HER2-low and Overexpression in Mucinous Ovarian Cancer: Analysis of ASCO/CAP and ToGA Immunohistochemical Scoring.
Han R; Madariaga A; Gonzalez-Ochoa E; Smith AC; Wang L; Lheureux S; Rouzbahman M
Int J Gynecol Pathol; 2024 May; 43(3):275-283. PubMed ID: 38436360
[TBL] [Abstract][Full Text] [Related]
2. Performance of HER2 DAKO HercepTest and Ventana 4B5 immunohistochemical assays on detecting HER2 gene-amplification in uterine serous carcinomas.
Navarro Sanchez JM; Finkelman BS; Tyburski H; Turner BM; Moisini I; Katerji H; Varghese S; Wang X; Schiffhauer LM; Chen JJ; Hicks DG; Zhang H
Hum Pathol; 2024 May; 148():51-59. PubMed ID: 38740270
[TBL] [Abstract][Full Text] [Related]
3. Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis.
Turashvili G; Leung S; Turbin D; Montgomery K; Gilks B; West R; Carrier M; Huntsman D; Aparicio S
BMC Cancer; 2009 May; 9():165. PubMed ID: 19476653
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis.
Sun H; Kang EY; Chen H; Sweeney KJ; Suchko M; Wu Y; Wen J; Krishnamurthy S; Albarracin CT; Ding QQ; Foo WC; Sahin AA
Breast Cancer Res Treat; 2024 Jun; 205(2):403-411. PubMed ID: 38441847
[TBL] [Abstract][Full Text] [Related]
5. Novel approach to HER2 quantification using phosphor-integrated dots in human breast invasive cancer microarray.
Saito N; Matsuo T; Tsuda H; Yokota H; Okada H
PLoS One; 2024; 19(5):e0303614. PubMed ID: 38748758
[TBL] [Abstract][Full Text] [Related]
6. Concordance between pathologists and between specimen types in detection of HER2-low breast carcinoma by immunohistochemistry.
Wang J; Yoon E; Krishnamurthy S
Ann Diagn Pathol; 2024 Jun; 70():152288. PubMed ID: 38452457
[TBL] [Abstract][Full Text] [Related]
7. Atypical Co-amplification with Co-localization of HER2 Gene in Breast Cancer: Combined IHC/FISH Approach as per ASCO/CAP 2018 Guidelines for Targeted Therapy Eligibility.
Kate U; Pais A; Kamble N; Kandoor S; Sharma K
Indian J Surg Oncol; 2024 Mar; 15(1):8-11. PubMed ID: 38511042
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Dako HercepTest and Ventana PATHWAY anti-HER2 (4B5) tests and their correlation with silver
Miladinović M; Vučković L; Klisic A
Open Med (Wars); 2021; 16(1):1503-1512. PubMed ID: 34708154
[TBL] [Abstract][Full Text] [Related]
9. Best Practice No 176: Updated recommendations for HER2 testing in the UK.
Ellis IO; Bartlett J; Dowsett M; Humphreys S; Jasani B; Miller K; Pinder SE; Rhodes A; Walker R
J Clin Pathol; 2004 Mar; 57(3):233-7. PubMed ID: 14990588
[TBL] [Abstract][Full Text] [Related]
10. HER2 Molecular Marker Scoring Using Transfer Learning and Decision Level Fusion.
Tewary S; Mukhopadhyay S
J Digit Imaging; 2021 Jun; 34(3):667-677. PubMed ID: 33742331
[TBL] [Abstract][Full Text] [Related]
11. Navigating HER2-Low Testing in Invasive Breast Cancer: Update Recommendations for Pathologists.
Bornstein-Quevedo L; de Anda-González J; Lara-Torres CO; Flores-Gutiérrez JP; Dorantes-Heredia R; Bautista-Piña V; Zaragoza-Vargas P; Alcaraz-Wong A; Soto-Sañudo AK; Mendoza-Ramírez S; Salamanca-García M; Loyola-Rodríguez G; Gómez-Macías GS; Murguia-Perez M; De Luna-Sánchez M; Villalobos-Valencia R; Talamantes E; Arce-Salinas C
J Pers Med; 2024 Apr; 14(5):. PubMed ID: 38793049
[TBL] [Abstract][Full Text] [Related]
12. The prevalence and clinical significance of HER2 expression in prostate adenocarcinoma.
Estephan F; Lap CJ; Banagan J; Antonio M; Liu S; Diao G; Rozalen AZ; Rajendran R; Krasnow S; Subrahmanyam R; Nava VE; Jain M
Ann Diagn Pathol; 2023 Dec; 67():152219. PubMed ID: 38622987
[TBL] [Abstract][Full Text] [Related]
13. External Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: an experience on a regional scale.
Terrenato I; Arena V; Pizzamiglio S; Pennacchia I; Perracchio L; Buglioni S; Ercolani C; Sperati F; Costarelli L; Bonanno E; Baldini D; Candia S; Crescenzi A; Dal Mas A; Di Cristofano C; Gomes V; Grillo LR; Pasquini P; Pericoli MN; Ramieri MT; Di Stefano D; Ruco L; Scarpino S; Vitolo D; d'Amati G; Paradiso A; Verderio P; Mottolese M
J Exp Clin Cancer Res; 2013 Aug; 32(1):58. PubMed ID: 23965490
[TBL] [Abstract][Full Text] [Related]
14. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue - a review.
Fedchenko N; Reifenrath J
Diagn Pathol; 2014 Nov; 9():221. PubMed ID: 25432701
[TBL] [Abstract][Full Text] [Related]
15. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
16. Effect of HER2 expression status on the prognosis of patients with HR
Wang K; Du Q; Yu J; Li Y; Zhu X
Oncol Lett; 2023 Jul; 26(1):299. PubMed ID: 37323815
[TBL] [Abstract][Full Text] [Related]
17. The effect of an alternative chromosome 17 probe on fluorescence
Xu Z; Xu P; Fan W; Huang B; Cheng Q; Zhang Z; Wang P; Yu M
Exp Ther Med; 2019 Sep; 18(3):2095-2103. PubMed ID: 31410164
[TBL] [Abstract][Full Text] [Related]
18. An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelines.
O'Grady A; Allen D; Happerfield L; Johnson N; Provenzano E; Pinder SE; Tee L; Gu M; Kay EW
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):489-93. PubMed ID: 20661132
[TBL] [Abstract][Full Text] [Related]
19. Validation of a fully automated HER2 staining kit in breast cancer.
Moelans CB; Kibbelaar RE; van den Heuvel MC; Castigliego D; de Weger RA; van Diest PJ
Cell Oncol; 2010; 32(1-2):149-55. PubMed ID: 20203372
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
